Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer.

dc.authoridBilici, Ahmet/0000-0002-3192-456X
dc.authoridKEFELI, UMUT/0000-0001-6126-5377
dc.authorwosidBilir, Cemil/A-2491-2017
dc.authorwosidGumus, Mahmut/HTO-4176-2023
dc.authorwosidBilici, Ahmet/E-2062-2018
dc.authorwosidArslan, Cagatay/I-1932-2016
dc.authorwosidTANRIKULU ŞİMŞEK, EDA/AAD-8011-2022
dc.authorwosidKEFELI, UMUT/V-6023-2017
dc.contributor.authorKefeli, Umut
dc.contributor.authorArslan, Cagatay
dc.contributor.authorYildirim, Mahmut Emre
dc.contributor.authorIsikdogan, Abdurrahman
dc.contributor.authorKaradurmus, Nuri
dc.contributor.authorKarabulut, Bulent
dc.contributor.authorCubukcu, Erdem
dc.date.accessioned2024-06-12T11:22:27Z
dc.date.available2024-06-12T11:22:27Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.descriptionVirtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 04-08, 2021 -- ELECTR NETWORKen_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipAmer Soc Clin Oncolen_US
dc.description.sponsorshipAmgen Ilac Tic Ltd Sti, Turkeyen_US
dc.description.sponsorshipAmgen Ilac Tic Ltd Sti, Turkeyen_US
dc.identifier.doi10.1200/JCO.2021.39.15_suppl.e15561
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue15en_US
dc.identifier.urihttps://doi.org/10.1200/JCO.2021.39.15_suppl.e15561
dc.identifier.urihttps://hdl.handle.net/20.500.14551/25943
dc.identifier.volume39en_US
dc.identifier.wosWOS:000708120301226en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofJournal Of Clinical Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keywords]en_US
dc.titleReal-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer.en_US
dc.typeConference Objecten_US

Dosyalar